New Zealand markets closed

Novartis AG (NVS)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
91.46+0.20 (+0.22%)
At close: 04:00PM EDT
91.58 +0.12 (+0.14%)
After hours: 06:53PM EDT
Full screen
Loading interactive chart…
  • GlobeNewswire

    FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma

    68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah treatment demonstrated – of patients who achieved a complete response, 85% were still in response at 12 months1 Kymriah can be administered in the outpatient setting, offering increased flexibility and potentially reducing the burden of therapy for patients and their care teams1,2 Kymriah is now FDA

  • GlobeNewswire

    Sandoz appoints new Board representative to global AMR Industry Alliance

    Dr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (AMRIA)The Alliance brings together about 100 life science companies / associations in search of sustainable solutions to curb AMRSandoz, as largest global provider of generic antibiotics1, is committed to a pragmatic and balanced approach to address this growing global health threat Basel, May 27, 2020 — Sandoz is pleased to announce the appointment of

  • Motley Fool

    Why Regeneron Investors Shouldn't Fear Its Patent Cliff

    Biotechnology giant Regeneron's (NASDAQ: REGN) eye medication EYLEA is one of the best-selling blockbuster drugs around, generating $9.4 billion sales globally in 2021. The drug is approved for a number of eye diseases and has been a mainstay for Regeneron for the past decade. Although its patents are nearing the end of their lifespan, Regeneron has a number of new treatments that will step in to replace lost revenue.